StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Rein Therapeutics's price to book ratio was 0.9× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.2× to 2.7×, with a median of 0.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.9×+0.3
2025Dec 31, 20250.6×+0.1
2024Dec 31, 20240.5×−0.7
2023Dec 29, 20231.2×+0.8
2022Dec 30, 20220.5×−0.5
2021Dec 31, 20211.0×−2.3
2020Dec 31, 20203.3×+2.6
2019Dec 31, 20190.7×+0.2
2018Dec 31, 20180.5×−2.4
2017Dec 29, 20172.9×–

More Rein Therapeutics figures

See a number that looks wrong?